Prosecution Insights
Last updated: August 16, 2026
Application No. 18/683,860

AN APPARTUS AND METHOD FOR FRACTIONAL ABLATIVE TREATMENT OF TISSUE

Final Rejection §102§103
Filed
Feb 15, 2024
Priority
Sep 02, 2021 — provisional 63/240,119 +3 more
Examiner
HOLMES, REX R
Art Unit
3796
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
IPG PHOTONICS Corporation
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
938 granted / 1168 resolved
+10.3% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
43 currently pending
Career history
1209
Total Applications
across all art units

Statute-Specific Performance

§101
5.0%
-35.0% vs TC avg
§103
41.2%
+1.2% vs TC avg
§102
28.5%
-11.5% vs TC avg
§112
16.7%
-23.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1168 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant's arguments filed 6/17/26 have been fully considered but they are not persuasive. The Applicant argues that the Van Valen reference fails to teach the claimed ranged with sufficient specificity as to anticipate the claimed limitations. The Examiner respectfully disagrees. It is first noted that the claimed ranges are not specific since they are claimed in an open ended “inclusive” language. It is noted that the Applicant’s arguments are directed toward claim language that is not specifically claimed. Since the claimed ranges are “inclusive” they are directed toward the claims ranges plus extra undefined ranges, thereby failing to explicitly state the claimed limitations with sufficient specificity. Therefore, since the limitations that cited within the Van Valen reference meet the claimed limitations with sufficient specificity. It is further noted that the Applicant is arguing limitations in the subject’s speciation’s that are not in the claims and therefore they are moot. Regarding the 103 rejections, the Applicant argues that the art is non-analogous and therefore goes against MPEP 2141.01(a). The Examiner respectfully disagrees as all of the art is directed toward laser and laser systems. The Applicant’s arguments regarding claim 25 are valid and the claim is now objected to as being dependent from a rejected claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-2, 5, 12 and 27-28 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Van Valen et al. (U.S. Pub. 2013/0085484 hereinafter “Van Valen”). Regarding claims 1 and 27, Van Valen discloses a device and method for performing treatment of biological tissue, comprising: a laser system configured to provide a laser beam having a wavelength within a range of 3.0 microns (pm) to 3.25 pm inclusive (e.g. ¶49) and a spot size within a range of 10 microns to 45 microns inclusive (e.g. ¶48); and a controller coupled to the laser system and configured to scan the laser beam over the biological tissue in an injury pattern, the injury pattern having a pitch that is sized to be in a range of 0.1 mm to 1 mm inclusive (e.g. ¶95; [0.1-1mm pattern distance]). Regarding claims 2 and 28, Van Valen further discloses wherein the spot size is within a range of 30 micron to 45 micron inclusive (e.g. ¶48). Regarding claim 5, Van Valen further discloses wherein the injury pattern is an array of spots or lines (e.g. ¶31). Regarding claim 12, Van Valen further discloses wherein each spot in the array of spots and each line in the array of lines has an ablation depth within a range of 25 micron to 3000 micron inclusive (e.g. ¶45). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 3-4 and 13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Van Valen as applied to claims 1-2, 5, 12 and 27-28 above, and further in view of Fried et al. (U.S. Pat. 6,221,068 hereinafter “Fried”). Regarding claims 3-4, Van Valen discloses the claimed invention except for explicitly disclosing the radiant exposure of the laser system. However, Fried teaches that it is known to use a laser system with similar parameters and a radiant exposure between 30 and 4000J as set forth in Column 23, lines 49-53 to provide radiant exposure that is enough to provide therapy but not enough to cause injury. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the system as taught by Van Valen, with the radiant exposure as taught by Fried, since such a modification would provide the predictable results of using known values that are enough to provide therapy but not enough to cause injury. Regarding claim 13, Van Valen discloses the claimed invention except for explicitly disclosing the intensity profile being a quasi-gaussian/flat top profile. However, Fried teaches that it is known to use a laser system with similar parameters and a gaussian profile as set forth in Column 23, lines 49-53 to provide targeted exposure while minimizing exposure on the edges of the beam. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the system as taught by Van Valen, with the gaussian profile as taught by Fried, since such a modification would provide the predictable results of targeted exposure while minimizing exposure on the edges of the beam. Claim(s) 6-8, 10-11 and 29-31 is/are rejected under 35 U.S.C. 103 as being unpatentable over Van Valen as applied to claims 1-2, 5, 12 and 27-28 above, and further in view of Sercel et al. (U.S. Pub. 2015/0179523 hereinafter “Sercel”). Regarding claims 6-8 and 29-31, Van Valen discloses the claimed invention except for explicitly disclosing the density and depth of the spots and lines. However, Sercel teaches that it is known to use a laser system with similar that provides for spots with a density in the range of 100-10000 spots per centimeter a depth of 25-3000 microns as set forth in Figure 18A and Paragraphs 53, 95-97 to provide a density and depth that provides effective ablation. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the system as taught by Van Valen, with the density and depth as taught by Sercel, since such a modification would provide the predictable results of providing a density and depth that provides effective ablation. Regarding claims 10-11, Van Valen discloses the claimed invention except for explicitly disclosing the density and depth of the spots and lines. However, Sercel teaches that it is known to use a laser system with similar that provides for spots decreased spots near the array edge as set forth in Paragraph 62 to provide reduced energy at the edges to provide separation and reduced cracking of the tissue. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the system as taught by Van Valen, with the reduced density of spots at the edges as taught by Sercel, since such a modification would provide the predictable results of providing reduced energy at the edges to provide separation and reduced cracking of the tissue. Claim(s) 19-20, 23-24 and 26 is/are rejected under 35 U.S.C. 103 as being unpatentable over Van Valen as applied to claims 1-2, 5, 12 and 27-28 above, and further in view of Lin (U.S. Pat. 6,258,082) and Borguet et al. (U.S. Pub. 2010/0321767 hereinafter “Borguet”). Regarding claims 19-20 and 23, Van Valen discloses the claimed invention except for explicitly disclosing the how the handpiece of figure 12 is constructed. However, Lin teaches a laser system with similar construction and parameters that teaches a laser source(s) (e.g. 19, 20), a wavelength conversion (e.g. 3), a scanner (e.g. 4), a optical focusing system (e.g. 5), and an optical fiber(s) (e.g. 21, 22) to supply the laser energy. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the system as taught by Van Valen, with laser handle construction as taught by Lin, since such a modification would provide the predictable results of using well-known laser delivery handle construction to provide laser therapy. Van Valen in view of Lin teaches the claimed device, but fails to explicitly state that the generator is a difference frequency generator that comprises a optical parametric oscillator. However, Borguet teaches that it is known to use OPO to provide exact frequency mixing to provide mid-IR frequencies for treatment as taught in Paragraphs 33 and 77. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the system as taught by Van Valen in view of Lin, with OPO difference frequency generators as taught by Borguet, since such a modification would provide the predictable results of using well-known frequency mixing to provide mid-IR frequencies for treatment. Regarding claim 24, meeting the limitations of claim 19 above, Lin further discloses wherein the laser module comprises two diode pumped fiber laser sources (e.g. Abstract, Column 9, lines 32-42). Regarding claims 26, meeting the limitations of claim 19 above, Borguet further teaches wherein laser radiation emitted from each of the two diode pumped fiber laser sources is mixed and delivered to the difference frequency generator by the optical fiber (e.g. ¶¶33, 77). Allowable Subject Matter Claim 25 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Fermann et al. (U.S. Pub. 2014/0219296) – discloses a fiber based mid-IR sources producing very short pulses and/or mid-IR sources based on a mode locked fiber lasers are utilized. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to REX R HOLMES whose telephone number is (571)272-8827. The examiner can normally be reached Monday-Thursday 7:00AM-5:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached at (571) 270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REX R HOLMES/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Feb 15, 2024
Application Filed
Mar 19, 2026
Non-Final Rejection mailed — §102, §103
Jun 17, 2026
Response Filed
Jul 29, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702834
SYSTEMS AND METHODS FOR MEASURING AND ALTERING BRAIN ACTIVITY RELATED TO FLEXIBLE BEHAVIOR
3y 3m to grant Granted Aug 11, 2026
Patent 12702351
DIABETIC FOOT ANALYSIS APPARATUS, AND DIABETIC FOOT MANAGEMENT SYSTEM
3y 0m to grant Granted Aug 11, 2026
Patent 12690798
MEDICAL DEVICE AND METHOD FOR DETECTING ARRHYTHMIA
3y 9m to grant Granted Jul 28, 2026
Patent 12685493
ALARM MONITORING AND EVALUATION
3y 7m to grant Granted Jul 21, 2026
Patent 12685868
An Implantable Medical Device Configured to Provide an Intra-Cardiac Function
3y 0m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+18.3%)
2y 10m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1168 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month